Your H. Pylori Keeps Coming Back. Your Genes May Be Why.

TNF-alpha is your immune system’s primary weapon against bacterial invaders. It signals immune cells to attack, increases intestinal barrier integrity, and orchestrates the inflammatory response needed to clear pathogens from your gut. Without sufficient TNF signaling, your body struggles to mount an effective attack.

The TNF -308G>A variant, present in roughly 30 percent of people with European ancestry, reduces TNF-alpha production. People with the A allele produce less TNF-alpha, which means a weaker inflammatory response to H. pylori. Your immune system essentially sends fewer soldiers to the battlefield.

This shows up as persistent or recurrent H. pylori infection despite treatment. Your bacteria don’t get cleared completely, or your gut doesn’t recognize and attack the stragglers after antibiotics. You also experience more prolonged inflammation and slower healing of the stomach lining.

IL-6 is a master inflammatory signaling molecule. It coordinates the transition from the initial acute immune response to sustained, targeted immunity. The right amount of IL-6 helps your body recognize H. pylori and organize an effective counterattack. Too little, and your immune system never gets the signal to mount a full response.

The IL6 -174G>C variant, carried by roughly 40 percent of the population, shifts your baseline IL-6 production. C allele carriers produce lower IL-6 levels, resulting in a dampened inflammatory response to infection. Your immune system responds more slowly and with less coordinated power.

With lower IL-6, H. pylori persists longer in your stomach because your body isn’t generating the sustained inflammatory message needed to clear it. After treatment, you also experience slower immune recovery and a weaker ability to prevent reinfection.

IL-1 beta is the first responder of inflammation. It’s released when your immune cells detect a threat, and it starts the cascade that recruits more immune cells, increases stomach acid production, and initiates the inflammatory response. Without IL-1 beta signaling, your body is slower to recognize H. pylori as a threat.

The IL1B rs16944 variant, present in roughly 35 to 40 percent of people, influences IL-1 beta production levels. Certain IL1B variants reduce IL-1 beta production, blunting your initial immune response to H. pylori. Your body is slower to recognize the infection as something that needs fighting.

This genetic blunting shows up as a delayed or weak acute phase response. You may not feel as sick when you have H. pylori (which feels like a positive, but isn’t). Your immune system is also slower to kick into gear during antibiotic treatment, which means the bacteria have more time to hide or form biofilms before the full immune assault arrives.

FUT2 controls which carbohydrate structures appear on the surface of your gut cells and in your saliva. These structures act as food for beneficial bacteria. People with two functional copies of FUT2 are “secretors,” meaning beneficial bacteria thrive in their gut. Non-secretors, lacking one or both functional copies, have a very different microbiome composition.

The FUT2 rs601338 variant determines secretor status. Non-secretors, roughly 20 percent of the population, have microbiome compositions that provide less resistance to H. pylori colonization. Their gut bacteria are less diverse and less able to out-compete pathogenic species for resources and space.

For non-secretors, this means H. pylori colonizes more easily and persists more stubbornly. After antibiotic treatment wipes out your gut bacteria (good and bad), your microbiome recovers more slowly and into a composition that doesn’t naturally suppress H. pylori regrowth. You’re also at higher risk for post-treatment dysbiosis and nutrient absorption problems.

The VDR is the cellular lock that vitamin D fits into. When vitamin D binds to VDR, it activates genes that strengthen your intestinal barrier, promote beneficial bacteria, and coordinate immune responses. People with certain VDR variants have reduced vitamin D signaling, meaning even adequate vitamin D levels don’t produce full protective effects.

Common VDR variants like FokI (rs2228570) and BsmI (rs1544410) affect receptor function and expression. People carrying less efficient VDR variants require higher vitamin D levels to achieve the same protective signaling. At standard vitamin D levels, their intestinal barrier remains compromised.

With a weak VDR, your gut lining doesn’t repair properly after H. pylori damage and antibiotic treatment. Your intestinal tight junctions remain leaky, allowing bacterial lipopolysaccharide to trigger chronic inflammation. You also have reduced production of antimicrobial peptides and beneficial bacteria, which means H. pylori regrows more easily.

MTHFR converts dietary folate into its active form, 5-methyltetrahydrofolate (5-MTHF). Your body uses 5-MTHF to synthesize DNA, repair cells, and produce glutathione, your master antioxidant. When MTHFR is inefficient, folate sits unused while your cells are starved of the active form they need.

The MTHFR C677T variant, carried by roughly 40 percent of the population, reduces enzyme efficiency by 40 to 70 percent in homozygous carriers. You can eat a perfect diet and still be functionally depleted of active folate at the cellular level. Your gut cells can’t repair damage quickly enough.

H. pylori eradication requires rapid cell turnover in your stomach lining. With low MTHFR activity, your gut epithelium repairs slowly after antibiotic damage. You also have reduced glutathione production, which means oxidative stress builds up and kills beneficial bacteria preferentially. Your immune cells also perform poorly, making it harder to sustain the response needed to prevent H. pylori regrowth.